Cost-Effectiveness Analysis of Statins for Treatment of Hospitalized COVID-19 Patients

1-3Ronald Chow BMSc FRSPH, 2Elizabeth Horn Prsic MD, 3-5Hyun Joon Shin MD ScD MPH MS

1Yale School of Public Health, Yale University, New Haven, CT, United States of America;
2Yale New Haven Health, Yale School of Medicine, Yale University, New Haven, CT, United States of America;
3Hanyang Impact Science Research Center, Seoul, Korea;
4Lemuel Shattuck Hospital, Jamaica Plain, MA, United States of America;
5Brigham and Women’s Hospital, Boston, MA, United States of America.

Correspondence:

Ronald Chow
Department of Chronic Disease Epidemiology, Yale School of Public Health
60 College Street, New Haven, CT 06510, USA
Email: ronald.chow@yale.edu

Hyun Joon Shin, Chief of Cardiology
Division of Cardiology, Department of Medicine, Lemuel Shattuck Hospital, Massachusetts Department of Health
170 Morton St, Jamaica Plain, MA 02130, USA
Tel: +1-617-522-8110; E-mail: hyun.shin@mass.gov

Disclosures: None

Abstract Word Count: 191
Manuscript Word Count: 1103

Tables: 1
Figures: 1

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
ABSTRACT

Introduction: A recent systematic review and meta-analysis by our group reported on thirteen published cohorts investigating 110,078 patients. Patients administered statins after their COVID-19 diagnosis and hospitalization were found to have a lower risk of mortality. Given this reported superiority, a logical next question would be whether statins are cost-effective treatment options for hospitalized COVID-19 patients. In this paper, we report on a cost-effectiveness analysis of statin-containing treatment regimens for hospitalized COVID-19 patients, from a United States healthcare perspective.

Methods: A Markov model was used, to compare statin use and no statin use among hospitalized COVID-19 patients. The cycle length was one week, with a time horizon of 4 weeks. A Monte Carlo microsimulation, with 20,000 samples were used. All analyses were conducted using TreeAge Pro Healthcare Version 2021 R1.1.

Results: Treatment of hospitalized COVID-19 patients with statins was both cheaper and more effective than treatment without statins; statin-containing therapy dominates over non-statin therapy.

Conclusion: Statin for treatment of COVID-19 should be further investigated in RCTs, especially considering its cost-effective nature. Optimistically and pending the results of future RCTs, statins may also be used broadly for treatment of hospitalized COVID-19 patients.

Keywords: statins, COVID-19, cost-effectiveness analysis
INTRODUCTION

The COVID-19 pandemic, as declared by the World Health Organization on March 12, 2020\(^1\), has been an ongoing pandemic for over a year, at the time of this writing. Many potential treatments have been explored, including statins. Mechanistically, statins may inhibit 3-hydroxyglutaryl-CoA (HMG-CoA) reductase in cells, and reduce a cytokine storm\(^2\-4\).

A recent systematic review and meta-analysis by our group reported on thirteen published cohorts investigating 110,078 patients. Patients administered statins after their COVID-19 diagnosis and hospitalization were found to have a lower risk of mortality – hazard ratio of 0.53, 95% CI: 0.46-0.61, and odds ratio of 0.57, 95% CI: 0.43-0.75. Given this reported superiority, a logical next question would be whether statins are cost-effective treatment options for hospitalized COVID-19 patients.

In this paper, we report on a cost-effectiveness analysis of statin-containing treatment regimens for hospitalized COVID-19 patients, from a United States healthcare perspective.

METHODS

The Model

A Markov model was used, to compare statin use and no statin use among hospitalized COVID-19 patients (Figure 1). There were four assumed health states – “Hospitalized, Non-ICU”, “Hospitalized, ICU”, “Discharged” and “Dead”. Patients treated with statins started in the “Hospitalized, Non-ICU” health state, and may or may not experience a drug-related adverse event during the cycle. If patients experienced liver or muscle toxicity, statins were discontinued.
Patients either remained in the “Hospitalized, Non-ICU” health state, or transitioned to one of the three other health states. For patients who were admitted to the ICU, we assumed that they would be transferred back to non-ICU inpatient care prior to discharge, or died. We also assumed that patients who were discharged would not be readmitted to the hospital for COVID-19, within 1 month.

The cycle length was one week, with a time horizon of 4 weeks. No discounting rate was used, due to the acute timeline. A Monte Carlo microsimulation, with 20,000 samples were used. All analyses were conducted using TreeAge Pro Healthcare Version 2021 R1.1.

**Probabilities**

We sourced 1-week probability of death, discharge and ICU admission for non-statin hospitalized COVID-19 patients from Zhang *et al* \(^5\) and Rodriguez-Nava *et al* \(^6\). From Zhang *et al* \(^5\), we computed the 1-week probability from their 4-week Kaplan-Meier curve statistics. We assumed that probabilities reported by Rodriguez-Nava *et al* \(^6\) were 4-week probabilities, and computed 1-week probability from it. Probability of death among statin patients was computed, using relative risks reported from a prior meta-analysis (Chow *et al* \(^7\)) and the probability reported by Zhang *et al* \(^5\) for non-statin patients. Probability of discharge and ICU admissions among statin patients was also sourced from Zhang *et al* \(^5\); probability of death among ICU patients receiving statins was extracted from Rodriguez-Nava *et al* \(^6\). The probabilities for liver and muscle toxicity were sourced from Gitlin *et al* \(^8\). Beta distributions were used, to model probabilities (Table 1).
Effectiveness

Utilities for non-ICU hospitalization and ICU hospitalization were noted from Cyrus et al. We assumed utilities for those who were discharged, died, experienced liver toxicity and experienced muscle toxicity. We conservatively assumed a disutility of -0.2 for liver and muscle toxicity, which would be a greater disutility than a patient’s health state changing from non-ICU hospitalization to ICU-hospitalization. Gamma distributions were used, for utility associated with hospitalization. Triangular distributions were used, for disutility associated with liver and muscle toxicity.

Costs

We calculated the cost of statins from the US Department of Health & Human Services, as the average cost of atorvastatin 10mg, simvastatin 40mg, pravastatin 40mg and lovastatin 40mg. We assumed price to range +/- 50%. The cost for non-ICU hospitalization was calculated using the 1-day average hospitalization cost of approximately $2,000 from the World Health Organization, and varied costs +/- 50%. We used the one-day cost of ICU hospitalization with mechanical ventilation from the Dasta et al. paper, and calculated a lower-bound range from the one-day cost of ICU hospitalization after stabilization on day 3. The upper-bound was calculated, to produce a symmetric range. A uniform distribution was used, to represent costs.

RESULTS

The mean cost for patients receiving statins was $31,623 (SD $20,331), whereas the mean cost for patients not receiving statins was $33,218 (SD $25,440). The mean effectiveness for the two cohorts were 1.73 (SD 0.96) and 1.71 (SD 1.00), respectively. Treatment of hospitalized
COVID-19 patients with statins was both cheaper and more effective than treatment without statins; statin-containing therapy dominates over non-statin therapy.

**DISCUSSION**

To our knowledge, this is the first cost-effectiveness analysis reporting on statins used for the treatment of hospitalized COVID-19 patients. We report herein that treatment with statins, relative to without statins, is both cheaper and more effective.

In an ideal world, this conclusion would carry little weight, as ideally most of the populace would have been vaccinated against COVID-19 and thereby very few incident cases would occur. Unfortunately, distribution of developed vaccines has been slow, and only a few developed countries have enough vaccines for their entire population\(^{13,14}\). Furthermore, variants of COVID-19 may escape immunity from vaccination\(^{15}\). In light of this, new COVID-19 cases will likely continue to emerge and treatment will be necessary, rather than prevention.

At the time of this writing in April 2021, remdesivir, systemic glucocorticoid and tocilizumab are recommended for patients with severe COVID-19 pneumonia\(^ {16}\). There is currently no safe treatment for patients with non-severe COVID-19. Given the results of our prior systematic review\(^ {7}\), and now this cost-effectiveness analysis suggesting statin-containing treatments are both cheaper and more effective, statins should be further investigated for use in non-severe COVID-19 patients. Statin therapy may lead to side effects of myopathy and liver toxicity, but these adverse events typically reverse, after discontinuation of statins.
We eagerly await the results of the ongoing COLSTAT trial, investigating colchicine/statins for the prevention of COVID-19. These results will hopefully provide insight as to whether statins are also appropriate in the prevention setting.

This study was not without limitations. Our underlying probabilities were sourced from observational studies, and therefore patients receiving and not receiving statins may have unbalanced characteristics that may lead to confounding. To account for potential imbalances, we used adjusted probabilities, from multivariable models. We also used beta distributions for probabilities, to account for potential variation in measured effectiveness relative to true effectiveness/efficacy. Another limitation is the omission of other possible side effects including statin-induced dementia\textsuperscript{17} and statin-induced diabetes\textsuperscript{18}. These adverse events are likely of marginal concern in patients with immediate risk of COVID-19 pneumonia, where the interest of treatment is improved health state in a very acute timeline until stabilization after COVID-19 infection. This differs from prior studies and cost-effectiveness analyses of statins in other settings, which report long term side effect of statins, including diabetes and dementia. It is also important to note that the link between dementia and statins is unclear at this time.

In conclusion, treatment of hospitalized COVID-19 patients led to better effectiveness, but also cheaper cost. Statin for treatment of COVID-19 should be further investigated in RCTs, especially considering its cost-effective nature. Optimistically and pending the results of future RCTs, statins may also be used broadly for treatment of hospitalized COVID-19 patients.

REFERENCES
1. Chow R, Elsayed S, Lock M. How robust are the results of one of the first positive trials of hydroxychloroquine for treatment of COVID-19? medRxiv 2020


Table 1. Inputs for Markov Model – Statin Use After Hospitalization

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Point Estimate</th>
<th>Range</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>One-Week Rate</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Statin Arm</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hospitalized, Non-ICU</td>
<td>0.82</td>
<td>N/A</td>
<td>Chow et al(^7)</td>
</tr>
<tr>
<td>Hospitalized, ICU</td>
<td>0.02</td>
<td>N/A</td>
<td>Zhang et al(^6)</td>
</tr>
<tr>
<td>Discharge</td>
<td>0.15</td>
<td>N/A</td>
<td>Zhang et al(^6)</td>
</tr>
<tr>
<td>Death</td>
<td>0.01</td>
<td>N/A</td>
<td>Chow et al(^7)</td>
</tr>
<tr>
<td>Hospitalized, ICU</td>
<td>0.94</td>
<td>N/A</td>
<td>Rodriguez-Nava et al(^6)</td>
</tr>
<tr>
<td>Hospitalized, Non-ICU</td>
<td>0.06</td>
<td>N/A</td>
<td>Rodriguez-Nava et al(^6)</td>
</tr>
<tr>
<td>Toxicity</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liver</td>
<td>0.01</td>
<td>N/A</td>
<td>Gitlin et al(^8)</td>
</tr>
<tr>
<td>Muscle</td>
<td>0.10</td>
<td>N/A</td>
<td>Gitlin et al(^8)</td>
</tr>
<tr>
<td>Non-Statin Arm</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hospitalized, Non-ICU</td>
<td>0.79</td>
<td>N/A</td>
<td>Zhang et al(^5)</td>
</tr>
<tr>
<td>Hospitalized, ICU</td>
<td>0.03</td>
<td>N/A</td>
<td>Zhang et al(^5)</td>
</tr>
<tr>
<td>Discharge</td>
<td>0.16</td>
<td>N/A</td>
<td>Zhang et al(^5)</td>
</tr>
<tr>
<td>Death</td>
<td>0.02</td>
<td>N/A</td>
<td>Zhang et al(^5)</td>
</tr>
<tr>
<td>Hospitalized, ICU</td>
<td>0.84</td>
<td>N/A</td>
<td>Rodriguez-Nava et al(^6)</td>
</tr>
<tr>
<td>Hospitalized, Non-ICU</td>
<td>0.16</td>
<td>N/A</td>
<td>Rodriguez-Nava et al(^6)</td>
</tr>
<tr>
<td><strong>Utilities</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Health States</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hospitalized, Non-ICU</td>
<td>0.847</td>
<td>0.83 to 0.87</td>
<td>Cyrus et al(^9)</td>
</tr>
<tr>
<td>Hospitalized, ICU</td>
<td>0.629</td>
<td>0.40 to 0.91</td>
<td>Cyrus et al(^9)</td>
</tr>
<tr>
<td>Discharged</td>
<td>1.0</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Death</td>
<td>0.0</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Toxicity</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liver</td>
<td>-0.20</td>
<td>-0.10 to -0.30</td>
<td>N/A</td>
</tr>
<tr>
<td>Muscle</td>
<td>-0.20</td>
<td>-0.10 to -0.30</td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Costs</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Statin Arm</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Added Cost: Statin</td>
<td>$0.93</td>
<td>$0.47 to $1.40</td>
<td>US Department of Health &amp; Human Services(^10)</td>
</tr>
<tr>
<td>Non-Statin Arm</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hospitalized, Non-ICU</td>
<td>$14,000</td>
<td>$7,000 to $21,000</td>
<td>World Health Organization(^11)</td>
</tr>
<tr>
<td>Hospitalized, ICU</td>
<td>$76,500</td>
<td>$28,000 to $125,000</td>
<td>Dasta et al(^12)</td>
</tr>
</tbody>
</table>

Legend:
N/A - not applicable
Figure 1. State-Transition Diagram

Statin

- Hospitalized, Non-ICU
  - No Drug Adverse Events
  - Liver or Muscle Toxicity
    - Dead
    - Discharged

- Hospitalized, ICU
  - No Drug Adverse Events
  - Liver or Muscle Toxicity
    - Dead
    - Discharged

No Use of Statins

- Hospitalized, Non-ICU
  - No Drug Adverse Events
  - Liver or Muscle Toxicity
    - Dead
    - Discharged

- Hospitalized, ICU
  - No Drug Adverse Events
  - Liver or Muscle Toxicity
    - Dead
    - Discharged

All rights reserved. No reuse allowed without permission.